BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33811160)

  • 21. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
    Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
    Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments.
    Martinelli P; Schaaf O; Mantoulidis A; Martin LJ; Fuchs JE; Bader G; Gollner A; Wolkerstorfer B; Rogers C; Balıkçı E; Lipp JJ; Mischerikow N; Doebel S; Gerstberger T; Sommergruber W; Huber KVM; Böttcher J
    ChemMedChem; 2023 Mar; 18(6):e202200686. PubMed ID: 36649575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
    Dong YB; Yang HL; Elliott MJ; McMasters KM
    Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
    Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
    DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
    Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
    Ma Y; North BJ; Shu J
    Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.
    Koh DW; Powell DP; Blake SD; Hoffman JL; Hopkins MM; Feng X
    Oncol Rep; 2015 Sep; 34(3):1589-98. PubMed ID: 26178079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
    Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
    Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
    Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
    Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
    Cai Y; Zhao B; Liang Q; Zhang Y; Cai J; Li G
    Eur J Pharmacol; 2017 Aug; 809():87-97. PubMed ID: 28506909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors.
    Khan I; Kashani-Sabet M
    Clin Exp Metastasis; 2024 Apr; ():. PubMed ID: 38683257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New inhibitors for the BPTF bromodomain enabled by structural biology and biophysical assay development.
    Ycas PD; Zahid H; Chan A; Olson NM; Johnson JA; Talluri SK; Schonbrunn E; Pomerantz WCK
    Org Biomol Chem; 2020 Jul; 18(27):5174-5182. PubMed ID: 32588860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
    Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
    Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atp-bound topoisomerase ii as a target for antitumor drugs.
    Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
    J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase II binds nucleosome-free DNA and acts redundantly with topoisomerase I to enhance recruitment of RNA Pol II in budding yeast.
    Sperling AS; Jeong KS; Kitada T; Grunstein M
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12693-8. PubMed ID: 21771901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Chromatin Remodeling Protein Bptf Promotes Posterior Neuroectodermal Fate by Enhancing Smad2-Activated wnt8a Expression.
    Ma Y; Liu X; Liu Z; Wei S; Shang H; Xue Y; Cao Y; Meng A; Wang Q
    J Neurosci; 2015 Jun; 35(22):8493-506. PubMed ID: 26041917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.